Paper38406830
Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022.
Li X and 12 others. Emerg Microbes Infect, 2024. Cited by 14 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022. Papers, record 38406830. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38406830
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ceftazidime | Major topic |
| Pseudomonas Infections | Major topic |
| Azabicyclo Compounds | Major topic |
| Humans | |
| Pseudomonas aeruginosa | |
| Anti-Bacterial Agents | |
| Drug Resistance, Multiple, Bacterial | |
| Drug Combinations | |
| Genomics | |
| Microbial Sensitivity Tests | |
| beta-Lactamases |
Source PubMed
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18,625,772 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. | Antimicrob Agents Chemother | 2008 | https://conductscience.org/library/papers/18625772 | PubMed |
| 2 | 35,974,990 | High prevalence of blaVEB , blaGES and blaPER genes in beta-lactam resistant clinical isolates of Pseudomonas aeruginosa. | AIMS Microbiol | 2022 | https://conductscience.org/library/papers/35974990 | PubMed |
| 3 | 25,870,070 | Molecular characterization of ISCR1-mediated blaPER-1 in a non-O1, non-O139 Vibrio cholerae strain from China. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/25870070 | PubMed |
| 4 | 26,248,364 | Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/26248364 | PubMed |
| 5 | 27,622,530 | Molecular Mechanism of Avibactam-Mediated β-Lactamase Inhibition. | ACS Infect Dis | 2015 | https://conductscience.org/library/papers/27622530 | PubMed |
| 6 | 29,514,274 | Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. | J Antimicrob Chemother | 2018 | https://conductscience.org/library/papers/29514274 | PubMed |
| 7 | 33,083,833 | Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections. | J Antimicrob Chemother | 2021 | https://conductscience.org/library/papers/33083833 | PubMed |
| 8 | 31,709,791 | Structural Insight into the Mechanism of Inhibitor Resistance in CTX-M-199, a CTX-M-64 Variant Carrying the S130T Substitution. | ACS Infect Dis | 2020 | https://conductscience.org/library/papers/31709791 | PubMed |
| 9 | 37,212,660 | Insertion of ISPa1635 in ISCR1 Creates a Hybrid Promoter for blaPER-1 Resulting in Resistance to Novel β-lactam/β-lactamase Inhibitor Combinations and Cefiderocol. | Antimicrob Agents Chemother | 2023 | https://conductscience.org/library/papers/37212660 | PubMed |
| 10 | 32,246,147 | In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/32246147 | PubMed |
| 11 | 37,140,037 | Proksee: in-depth characterization and visualization of bacterial genomes. | Nucleic Acids Res | 2023 | https://conductscience.org/library/papers/37140037 | PubMed |
| 12 | 34,484,166 | Emergence of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in a Widespread ST11 Carbapenem-Resistant Klebsiella pneumoniae Clone in China. | Front Microbiol | 2021 | https://conductscience.org/library/papers/34484166 | PubMed |
| 13 | 26,584,231 | OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. | J Chem Theory Comput | 2016 | https://conductscience.org/library/papers/26584231 | PubMed |
| 14 | 27,402,011 | Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations. | J Antimicrob Chemother | 2016 | https://conductscience.org/library/papers/27402011 | PubMed |
| 15 | 35,439,291 | Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). | Clin Infect Dis | 2022 | https://conductscience.org/library/papers/35439291 | PubMed |
| 16 | 36,399,436 | Hypermutator strains of Pseudomonas aeruginosa reveal novel pathways of resistance to combinations of cephalosporin antibiotics and beta-lactamase inhibitors. | PLoS Biol | 2022 | https://conductscience.org/library/papers/36399436 | PubMed |
| 17 | 16,420,040 | Novel procedure for modeling ligand/receptor induced fit effects. | J Med Chem | 2006 | https://conductscience.org/library/papers/16420040 | PubMed |
| 18 | 25,645,206 | Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. | J Antimicrob Chemother | 2015 | https://conductscience.org/library/papers/25645206 | PubMed |
| 19 | 21,905,107 | The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. | Proteins | 2011 | https://conductscience.org/library/papers/21905107 | PubMed |
| 20 | 33,045,347 | Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update. | Int J Antimicrob Agents | 2020 | https://conductscience.org/library/papers/33045347 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,479,024 | PER-14, a β-lactamase variant with reduced sensitivity to avibactam and relebactam. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/42479024 | PubMed |
| 42,429,474 | Emergence of ceftazidime-avibactam resistance mediated by KPC variants KPC-71 and KPC-78 in ST463 Pseudomonas aeruginosa. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/42429474 | PubMed |
| 41,892,432 | Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/41892432 | PubMed |
| 41,835,003 | The blaKPC-249 -mediated mechanism drives the transition of ST463 Pseudomonas aeruginosa from Ceftazidime-Avibactam sensitivity to resistance during clinical treatment. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/41835003 | PubMed |
| 41,630,025 | Genomic epidemiology and aztreonam-avibactam resistance mechanisms of Proteus mirabilis in china: an eight-year retrospective study. | Ann Clin Microbiol Antimicrob | 2026 | https://conductscience.org/library/papers/41630025 | PubMed |
| 41,195,361 | Study on resistance mechanisms and molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa to ceftazidime/avibactam in a certain region of China. | Front Cell Infect Microbiol | 2025 | https://conductscience.org/library/papers/41195361 | PubMed |
| 40,732,125 | Metagenome Analysis Reveals Changes in Gut Microbial Antibiotic Resistance Genes and Virulence Factors in Reintroduced Giant Pandas. | Microorganisms | 2025 | https://conductscience.org/library/papers/40732125 | PubMed |
| 40,600,143 | Identification of two KPC variants, KPC-204 and KPC-227, in ST11-K64 Klebsiella pneumoniae during prolonged hospitalization of a single patient. | Front Microbiol | 2025 | https://conductscience.org/library/papers/40600143 | PubMed |
| 40,142,580 | Antibiotic Resistance and Virulence Determinants of Pseudomonas aeruginosa Isolates Cultured from Hydrocarbon-Contaminated Environmental Samples. | Microorganisms | 2025 | https://conductscience.org/library/papers/40142580 | PubMed |
| 39,843,962 | Global phylogeography and genetic characterization of carbapenem and ceftazidime-avibactam resistant KPC-33-producing Pseudomonas aeruginosa. | NPJ Antimicrob Resist | 2025 | https://conductscience.org/library/papers/39843962 | PubMed |
| 39,592,545 | Multidrug resistance in Pseudomonas aeruginosa: genetic control mechanisms and therapeutic advances. | Mol Biomed | 2024 | https://conductscience.org/library/papers/39592545 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38406830
GET https://conductscience.org/api/papers/v1/38406830/references?page=2